



# Hansa's sustainability journey



Sustainability  
Report 2024



# Hansa's journey towards a more sustainable business

Over the last three years, Hansa Biopharma (Hansa) has continuously evolved its approach to sustainability, aligning to the changes happening within the Company and the external environment. New external reporting requirements alongside internal organization change including a growing commercial function and geographic expansion, have resulted in the Company considering how to best meet the needs of stakeholders within the context of sustainability.

This year's Sustainability Report outlines the continued efforts the Company has advanced and our focus for 2025. The report highlights our work to address high unmet medical need in our three core therapy areas – Autoimmune, Gene Therapy and Transplantation, as well as our continued focus on ensuring we are operating as a transparent, ethical business. Finally, we continue to believe that a diverse, inclusive, and supportive culture is integral to the Company's success.

#### About this report

This report covers the reporting period for the year ending 31 December 2024. Hansa Biopharma publishes a Sustainability Report every year in line with our financial annual reporting. The Company's Annual Report and Sustainability Report were published on 21 March 2025.

The Sustainability Report considers the Global Reporting Initiative's (GRI) reporting standard, see index on page 16. The Sustainability Report is not externally assured.

#### Contact:

stephanie.kenney@hansabiopharma.com

<b>Sustainability at Hansa</b>	<b>3</b>
CEO letter	4
Our sustainability strategy	5
<b>Sustainability Report</b>	<b>7</b>
GRI and CSRD	8
Hansa's Materiality Matrix	9
Hansa's sustainability strategy	10
Looking Ahead to 2025	15
<b>GRI Index</b>	<b>16</b>
GRI Index	17



# Sustainability at Hansa

In line with the Company's size and business focus, we take an agile approach to sustainability while ensuring we are meeting external requirements and standards.

To that end, we have identified key priorities that reflect both external requirements and standards as well as where our business is today. Sustainability is a mindset underpinned by our corporate values and behaviors.


We aim to align our sustainability reporting with the Global Reporting Initiative standards (GRI), the world's most widely used sustainability reporting standards and continually review changes and updates to the reporting legislation. Additionally, we are aware of, and continue to prepare to meet, new upcoming reporting legislation in line with the Corporate Sustainability Reporting Directive (CSRD) and set forth by the European Sustainability Reporting Standards (ESRS).

To that end, the Company completed its first Double Materiality Assessment (DMA) in 2024 engaging key stakeholders to evaluate material topics based on both impact and financial relevance.



29

different nationalities



66%

of all employees are women



15

countries in 2024 with reimbursement



Zero

cases of unethical or illegal behavior identified



100%

renewable energy used



95%

completion rate Great Place to Work survey

# CEO letter



Over the course of the last year, Hansa Biopharma has continued to evolve as a company and remains focused on our mission to deliver lifesaving immunomodulating therapies to people with rare, immune-mediated diseases. We have made significant progress with our exciting pipeline, including two unique molecules – imlifidase and HNSA-5487. And we have continued to work in Europe to ensure patients have access to imlifidase, conditionally approved under the brand name IDEFIRIX®, as a desensitization treatment for highly sensitized kidney transplant patients.

2024 also marked the first year we conducted a Double Materiality Assessment as a company. While not required at this time, we felt it was important to better understand the Company's impact on stakeholders and the environment as well as what opportunities influence Hansa's business.

The output – a list of prioritized material topics – provided us with invaluable insight and perspective on gaps in our sustainability strategy and areas of focus for effective risk management.

What is clear to me is that sustainability remains an important part of our business – what we do as well as how we do it. With a keen eye towards becoming a more sustainable, ethical and transparent organization, Hansa has the opportunity to deliver innovative new medicines to people in areas with high unmet need. And we need to do this in a way that benefits shareholders, clinicians and most importantly patients and caregivers.

I look forward to further embedding sustainability into our business as we expand into new geographies, look to attract dynamic, new talent, and broaden access to our innovative new medicines.

**Søren Tulstrup**  
President and CEO  
Hansa Biopharma AB

# Our sustainability strategy

The Company's sustainability strategy consists of three focus areas:



### Agenda 2024

The United Nations' Sustainable Development Goals include 17 Sustainable Development Goals (SDGs) that provide a vision for ending poverty and hunger, strategies that improve health and education, reduce inequality, spur economic growth as well as tackle climate change and preserve oceans and forests by 2030. Besides national governments and civil society, the private sector is encouraged to contribute. At Hansa, we have identified six SDGs where the Company can positively contribute.

- 3 GOOD HEALTH AND WELL-BEING Ensure healthy lives and promote well-being for all at all ages
- 5 GENDER EQUALITY Achieve gender equality and empower for all women and girls
- 8 DECENT WORK AND ECONOMIC GROWTH Promote sustained, inclusive, and sustainable economic growth, full and productive employment, and decent work for all
- 9 INDUSTRY, INNOVATION AND INFRASTRUCTURE Industry, Innovation and Infrastructure
- 10 REDUCE INEQUALITIES Reduce inequalities
- 16 PEACE, JUSTICE AND STRONG INSTITUTIONS Promote peaceful and inclusive societies for sustainable development, provide access to justice for all and build effective, accountable, and inclusive institutions at all levels
- 17 PARTNERSHIPS FOR GOALS Strengthen the means of implementation and revitalize the Global Partnership for Sustainable Development



# Hansa's sustainability strategy is built on four key principles

1

**Addressing unmet  
medical needs**

2

**Cultivating an engaged  
culture by fostering  
inclusivity, collaboration,  
and innovation**

3

**Making a difference by  
operating an ethical,  
transparent, and  
responsible business**

4

**Embracing sustainable  
decision-making  
and environmental  
stewardship**



# Sustainability Report

GRI and CSRD	8
Hansa's Materiality Matrix	9
Hansa's sustainability strategy	10
Looking Ahead to 2025	15

# GRI and CSRD

As in previous years, the company considered the Global Reporting Initiative's (GRI) reporting standard. Additionally, and in line with the CSRD and guided by the ESRS, the Company conducted a Double Materiality Assessment (DMA) in 2024.

This ensured alignment with evolving regulatory frameworks and industry best practices. Prior to this the Company conducted a materiality assessment in 2021.

The DMA was conducted to refine our understanding of key sustainability topics and their impact on stakeholders and the company. The DMA evaluated both the company's impact on stakeholders and the environment (impact materiality) and how external sustainability risks and opportunities influence Hansa's business (financial materiality).

Hansa proactively conducted the DMA to better position itself to meet the CSRD requirements for future reporting cycles. This approach reflects the company's commitment to transparency, strategic foresight, and continuous improvement, ensuring that sustainability remains a core focus while preparing for full compliance with future reporting obligations.

Hansa proactively conducted the DMA to better position itself to meet the CSRD requirements for future reporting cycles.

## Hansa took the following steps to conduct its DMA

1.

### Stakeholder identification & engagement

Conducted stakeholder mapping and engaged key internal and external groups to identify material topics, gather insights, and align with CSRD requirements.

2.

### Identifying long list of relevant topics

Identified a comprehensive 'long list' of over 60 sustainability topics across 15 areas, in alignment with regulations, global frameworks like GRI and SASB, MSCI and industry best practices.

3.

### Shortlisting material impacts, risks and opportunities

Refined the long list of 60 topics through stakeholder feedback and assessment of impacts, risks, and opportunities to arrive at 10 key material topics critical to Hansa's strategy.

4.


### Validating and finalizing the materiality matrix

Finalized the Materiality Matrix by validating the 10 topics with the Executive Committee, prioritizing six key areas while ensuring critical oversight for the remaining four topics.



# Hansa's Materiality Matrix

The DMA identified 10 material topics which the Executive Committee then analyzed and validated, resulting in the six most impactful and financially significant topics. These were plotted on a Materiality Matrix and will be leveraged as key areas for our sustainability strategy. You can read the full Double Materiality Assessment on the Company website at [HansaBiopharma\\_DoubleMaterialityAssessment\\_2024.pdf](#). The Assessment was published on February 18, 2025.



### Sustainability governance at Hansa

Hansa's Board of Directors acts as the highest governance body and is responsible for the approval of the overall business strategy including sustainability, company policies and the Code of Conduct.

## Hansa's sustainability strategy

# Addressing unmet medical need

Our commitment to addressing unmet medical needs goes beyond ensuring access to our medicines. We know that in order to have true impact on people's lives, we need to think holistically about addressing unmet need throughout the healthcare continuum.

To that end, collaboration with stakeholders across the healthcare ecosystem remains a core part of our business. In 2024, we continued to partner with professional societies, centers of excellence, individual key opinion leaders and clinicians, and patient advocacy groups to better understand the barriers to care and how to collaborate to deliver better patient outcomes.

In 2024, Hansa participated in over 120 medical events or scientific congresses including sponsorship of two symposia at international congresses to share the Company's clinical and scientific data and in some instances, educate clinicians on the unmet need of highly sensitized kidney transplant patients. We advanced 13 clinical trials in areas of high unmet need in Autoimmune Diseases, Gene Therapy, and Transplantation.

Additionally, we continued our work in Europe

and the United States (US) with patient advocacy groups, individual patient advocates, and policy makers to educate and advocate for access to new medicines.

Throughout the year, Hansa engaged with patient advocacy groups to better understand the needs of patients in autoimmune, gene therapy and transplantation.

For example, Hansa convened key opinion leaders and patient advocacy groups to discuss the opportunities that exist to improve patient care for highly sensitized kidney transplant patients. Insights gathered from the meeting are helping to inform our strategy and provide valuable perspective on how we can be a thoughtful, relevant partner to patient groups that are helping to educate, inform, and support patients waiting for a kidney transplant.

1



120

international, national and regional events in 2024 including symposia, expert meetings, and oral and poster presentations



13

ongoing clinical trials



12

patient advocacy groups supported across Europe and the US

## Hansa's sustainability strategy: Addressing unmet medical need continued



The table below outlines the funding we provided to patient advocacy groups in 2024.

PAG Name	Short description	Amount	Currency	Approx SEK	Country
<b>American Association of Kidney Patients (AAKP)</b>	Bronze level corporate membership in 2024 and for 2025	30,000	USD	334,800	US
<b>Asociación De Enfermos de Riñón (ADER)</b>	Corporate membership at 'Partner Newsletter' level to support ADER's work and the kidney patient community across Spain	10,000	EUR	119,200	Spain
<b>American Kidney Fund (AKF)</b>	Sponsorship of The Hope Affair(AKF's annual gala dinner) and Corporate Membership of AKF at Advocate level in 2024 and for 2025; supporting AKF's core mission to fight kidney disease and help people live healthier lives	30,000	USD	334,800	US
<b>Associazione Nazionale Emodializzati (ANED)</b>	Support for Annual national meeting including a session on "Equity in kidney transplantation"	10,000	EUR	119,200	Italy
<b>European Kidney Health Alliance (EKHA)</b>	Sponsorship of workshop on Organ Donation and Transplantation held at Hungarian embassy to the EU in January 2024 and silver level Corporate membership.	35,000	EUR	417,200	Belgium
<b>European Kidney Patients' Federation</b>	Corporate membership as 'Official Collaborators'	15,000	EUR	178,800	Spain
<b>EURORDIS</b>	2025 Membership of EURORDIS Roundtable of Companies (ERTC)	6,000	EUR	715,20	France
<b>Everylife Foundation for Rare Disease</b>	Membership of the Everylife Foundation Community Congress	7,500	USD	837,00	US
<b>Federación Nacional de Asociaciones ALCER</b>	Sponsorship of the ALCER National Congress for Renal People	4,000	EUR	476,80	Spain
<b>Kidney Research UK</b>	Annual membership of Kidney Research UK's Industry Partnership Programme	8,000	GBP	110,610	UK
<b>National Organization for Rare Disorders (NORD)</b>	Membership of the NORD Corporate Council as a 'Clinical Development Member'	10,000	USD	111,600	US
<b>Renaloo</b>	Support for the development of patient information and policy activities	30,000	EUR	357,600	France

Hansa engages with patient groups based on three key partnership principles – independence of patient groups, respect and clarity of purpose of advocates, and transparency in financial support provided. In 2024, the Company formalized these principles, creating and implementing a company policy on Interactions with Patient Advocacy Groups ("PAGs")

We updated a policy on Corporate Giving outlining the standards and principles governing Grants, Donations, Contributions, and Sponsorships provided by Hansa to Healthcare Professional Societies ("HPSs"), PAGs, and other organizations including research organizations, academia, and healthcare institutions (e.g., hospitals) engaged directly or indirectly in healthcare and the support of patients. In addition, an SOP on Corporate Giving to PAGs has been implemented to ensure company-wide awareness of a new centralized approach to PAG support.

Hansa's sustainability strategy:

# Cultivating an engaged culture by fostering inclusivity, collaboration, and innovation

2

Hansa places a premium on its culture and recognizes the criticality of continuing to evolve our culture to reflect a diverse and inclusive workplace. We continue to seek input and feedback from employees to ensure they develop and grow, and offer a healthy, safe work environment.

Each year Hansa participates in the Great Place to Work® survey to gather feedback from our employees on engagement and culture. In 2024, 95% of employees completed the survey, and Hansa was once again certified as a Great Place to Work in Sweden.

Our values serve as a guide to how we work together internally and in our interactions with external stakeholders and partners. At Hansa, we foster a culture of action, collaboration, and accountability, reflected in our core behaviors: being Doers, Team Players, and Self-Motivated.

Our leadership is built on the principles of Leading by Example, Bravery, and Empathy – ensuring that we make decisions with clarity, adapt to challenges with agility, and prioritize with a rigorous focus on impact.

Hansa's culture values authentic, transparent communication and encourages an inclusive and diverse workplace. Being authentic and feeling empowered to speak up remains a top priority for the Company. In 2024 there were 29 different nationalities working at Hansa and during the same year the company experienced low turnover (14%).

Grounded in individual development, benefits that drive exceptional performance, and meaningful work in a healthy, safe environment.

Employee development remains an important priority at Hansa. Throughout the year, all employees are encouraged to participate in training and also develop through in-role experiences. With their manager, each employee has an individual development plan, and an annual Performance Management process ensures employees and managers align on and discuss performance objectives and goals.

The Company provides benefits to employees to help ensure a healthy, safe and balanced work environment. These include preventative healthcare benefits, access to occupational health specialists, living donor leave, beneficial bikes, and free onsite vaccinations.



## Hansa's sustainability strategy:

# Making a difference by operating an ethical, responsible, and transparent business

3

Hansa continues to refine its support of employees to ensure business operations are conducted in an ethical, responsible, and transparent manner complying with laws and regulations. Continuous engagement between Hansa employees and the Legal and Compliance function ensures all employees are up to date on relevant principles, policies, and procedures and take personal accountability for interactions with external stakeholders are done consistently to ensure that Hansa employees take personal accountability for interactions with external stakeholders including partners, vendors, and collaborators.

Currently, the Legal and Compliance function reports directly to the CEO and plays an active role within the Executive Committee and Board of Directors. Additionally, the Company's Code of Conduct remains a foundational tool for interactions across the business including guidance on anti-corruption, medical ethics, diversity and inclusion, supplier selection, and sustainability. The Code of Conduct is reviewed periodically to ensure it remains in accordance with requirements and regulations and is readily accessible on Hansa's corporate website at [https://www.hansabiopharma.com/files/corporate-governance/HansaBiopharma\\_Code\\_of\\_Conduct\\_EN\\_220406.pdf](https://www.hansabiopharma.com/files/corporate-governance/HansaBiopharma_Code_of_Conduct_EN_220406.pdf).

Engagements with external stakeholders are aligned with Hansa's values, and we utilize

a Supplier Code for all contracts (<https://www.hansabiopharma.com/files/corporate-governance/210607-HansaBiopharma-BusinessPartnerSupplierCode.pdf>). We consistently conduct regular auditing and risk assessments to ensure the Code is upheld. Hansa utilizes a comprehensive vendor selection process categorizing vendors by impact to the business. Vendors must be qualified through an audit process and receive periodic reviews. Supplier screenings are also conducted to understand service specifications, change controls, issues and complaints and oversight plans.

In accordance with Sweden's Act on the Protection of Persons Reporting Irregularities (Sw. Lag (2021:890) om skydd för personer som rapporterar om missförhållanden), Hansa maintains a speak up platform as endorsed in the Code of Conduct. In 2024, no cases of illegal or unethical behavior were identified or reported via the speak up program.

All Hansa employees received training on personal data privacy protection and cyber security in 2024. During the year, eight reports of personal data breaches were identified and reported; however, none of these data breaches were found to pose a risk to an individual's rights or freedoms and did not require further action.

Over the course of the year, new policies were implemented governing the areas of global data privacy, including personal data breaches and retention; patient advocacy group engagement; digital and social media communications; and CMC processes. These policies were created in line with the growing needs of the company and reflect Hansa's agile adaptation to the ever-evolving legal and regulatory landscape.

Meeting regularly with external stakeholders including the financial and investment community ensures we are being transparent about our business and its progress. In 2024, Hansa held over 150 meetings with industry analysts and members of the financial community.

Hansa is committed to operating with the highest integrity and ethical standards, complying with laws and regulations, and driving personal accountability for employees, partners, and vendors.

## Hansa's sustainability strategy:

# Embracing sustainable decision making and environmental stewardship



Throughout 2024, the Company continued to embrace sustainable decision making from discovery to clinical trial design, to product launches and manufacturing. In 2024, 100% of energy was sourced from renewable sources primarily hydroelectric power. Wastewater produced at our facilities is handled as per local regulations and reported to relevant authorities. Waste assembled is also handled and sorted as required by local authorities.

This year's report reflects an overall decrease by 26% in Hansa's environmental footprint. This reflects more accurate reporting and granular data related to business travel as well as a reduction in Scope 3 (purchased goods and services, upstream transportation and distribution, capital goods) overall.

### Energy consumption in 2024 (tCO<sub>2</sub>)

Electricity	0.369
of which renewable	100%
District Heating	5.13
of which renewable	100%
District Cooling	0
<b>Total</b>	<b>5.502</b>

### Breakdown of scope 3 emissions by category

Purchased Goods and Services	4,860.0
Upstream Transportation and Distribution	503.6
Capital Goods	4.05
Business travel	341.7
Fuel- and energy-related activities	4.6
of which fuel and energy related activities	2.857
of which WTT - electricity	1.78
Waste Generated in Operations	0.093
Commercial and industrial waste combustion	0.004
of which Water waste	0.089
<b>Total</b>	<b>5,714.0</b>

### Emissions (in tCO<sub>2</sub>-eq)

Scope 1 – Mobile combustion	0
Scope 2 – Electricity, Heating, Cooling	5.5
Scope 3 – Value Chain	5,714.0
<b>Grand total</b>	<b>5,719.5</b>

Utilizing approaches that reduce the environmental impact of our business, Hansa is creating a default sustainable business from discovery and clinical trial design all the way to product manufacturing and launch.



# Looking Ahead to 2025

In 2025, Hansa will continue to evolve its sustainability strategy to align with the Company's overall objectives as well as external legislation and reporting requirements. Additionally, the Company will look to address any gaps in sustainability practices and implement effective risk management strategies. Further, we will continue to integrate sustainability into core business functions and decision-making processes. Finally, we will begin to prepare for publication of a comprehensive sustainability report in line with CSRD requirements.



# GRI Index

GRI Index

17



# GRI Index

GRI Standard	Disclosure	GRI Standard Disclosure description	Reference/response
<b>Universal standards</b>			
<b>GRI 2: General Disclosures 2021</b>	2-1	Organizational details	Annual Report page 30
	2-2	Entities included in the organization's sustainability reporting	Annual Report page 35
	2-3	Reporting period, frequency and contact point	"Reporting period: Calendar year ending 31 December 2024 Frequency of reporting: every year, in line with Hansa's annual and financial reporting Contact point: stephanie.kenney@hansabiopharma.com"
	2-4	Restatements of information	None made in the 2024 Sustainability Report
	2-5	External assurance	The 2024 Sustainability Report is not assured by an external third party
	2-6	Activities, value chain and other business relationships	Sustainability Report pages 10 and 11; Annual Report pages 4-6, 8, 9, 15-16, 18, 19, and 22-24
	2-7	Employees	Sustainability Report pages 3, 12 and 13
	2-8	Workers who are not employees	Sustainability Report page 12 and 13; Hansa does not report on all of the requested data
	2-9	Governance structure and composition	Sustainability Report page 13; Annual Report page 95
	2-10	Nomination and selection of the highest governance body	Annual Report page 97-98
	2-11	Chair of the highest governance body	Annual Report page 98
	2-12	Role of the highest governance body in overseeing the management of impacts	Sustainability Report pages 8 and 9; Annual Report page 98
	2-13	Delegation of responsibility for managing impacts	Sustainability Report pages 8 and 9 ; Annual Report page 98
	2-14	Role of the highest governance body in sustainability reporting	Sustainability Report page 9; Annual Report page 98
	2-15	Conflicts of interest	Included in Hansa's Compliance Reporting; Annual Report page 99-100
	2-16	Communication of critical concerns	Sustainability Report page 13; Annual Report page 32 and 67
	2-17	Collective knowledge of the highest governance body	Sustainability Report page 9; Annual Report page 98
	2-18	Evaluation of the performance of the highest governance body	Annual Report page 101
	2-19	Remuneration policies	Annual Report page 108
	2-20	Process to determine remuneration	Annual Report pages 35-37 and 108-113
	2-21	Annual total compensation ratio	Annual Report pages 112 and 113
	2-22	Statement on sustainable development strategy	Sustainability Report pages 5, 9 and 14; Annual Report pages 15, 35 and 36
	2-23	Policy commitments	Sustainability Report page 13; Annual Report page 67 and 106
	2-24	Embedding policy commitments	Sustainability Report page 13; Annual Report page 67 and 106
	2-25	Processes to remediate negative impacts	Sustainability Report page 13
	2-26	Mechanisms for seeking advice and raising concerns	Sustainability Report page 13
	2-27	Compliance with laws and regulations	Annual Report page 106
	2-28	Membership associations	Hansa Biopharma is a member of several industry associations
	2-29	Approach to stakeholder engagement	Sustainability Report pages 10 and 11
	2-30	Collective bargaining agreements	Hansa employees are not covered by collective bargaining agreements

## GRI Index continued

GRI Standard	Disclosure	GRI Standard Disclosure description	Reference/response
<b>GRI 3: Material Topics 2021</b>	3-1	Process to determine material topics	Sustainability Report pages 8 and 9
	3-2	List of material topics	Sustainability Report page 9
	3-3	Management of material topics	Sustainability Report pages 9 and 14
<b>Topic-specific standards</b>			
<b>GRI 200: Economic</b>			
GRI 201: Economic Performance	201-1	Direct economic value generated and distributed	Annual Report pages 45 and 46
GRI 203: Indirect Economic Impacts	203-2	Significant indirect economic impacts	Annual Report pages 32, 68 and 69
GRI 205: Anti-Corruption	205-1	Operations assessed for risks related to corruption	Sustainability Report page 13; Annual Report page 67
	205-2	Communication and training about anti-corruption policies and procedures	Sustainability Report page 13
	205-3	Confirmed incidents of corruption and actions taken	Sustainability Report page 13
<b>GRI 300: Environmental</b>			
GRI 302: Energy	302-1	Energy consumption within the organization	Sustainability Report page 14
GRI 303: Water and Effluents 2018	303-4	Water discharge	Sustainability Report page 14
GRI 305: Emissions	305-2	Energy indirect (Scope 2) GHG emissions	Sustainability Report page 14
	305-3	Other indirect (Scope 3) GHG emissions	Sustainability Report page 14
GRI 306: Waste 2020	306-3	Waste generated	Sustainability Report page 14
<b>GRI 400: Social</b>			
GRI 401: Employment 2016	401-1	New employee hires and employee turnover	Sustainability Report page 12
GRI 403: Occupational Health and Safety 2018	403-3	Occupational health services	Sustainability Report page 12
	403-6	Promotion of worker health	Sustainability Report page 12
GRI 404: Training and Education 2016	404-2	Programs for upgrading employee skills and transition assistance programs	Sustainability Report page 12
	404-3	Percentage of employees receiving regular performance and career development reviews	Sustainability Report page 12
GRI 405: Diversity and Equal Opportunity 2016	405-1	Diversity of governance bodies and employees	Sustainability Report pages 3 and 12
GRI 413: Local Communities 2016	413-1	Operations with local community engagement, impact assessments, and development programs	Sustainability Report pages 10 and 11
GRI 414: Supplier Social Assessment 2016	414-1	New suppliers that were screened using social criteria	Sustainability Report page 13
GRI 416: Customer Health and Safety 2016	416-1	Assessment of the health and safety impacts of product and service categories	Annual Report pages 4, 5 and 12-22
GRI 417: Marketing and Labeling 2016	417-1	Requirements for product and service information and labeling	Annual Report pages 33 and 34
GRI 418: Customer Privacy 2016	418-1	Substantiated complaints concerning breaches of customer privacy and losses of customer data	Sustainability Report page 13



**Hansa Biopharma AB**

P.O. Box 785  
SE-220 07 Lund, Sweden

Phone: +46 46 16 56 70  
E-mail: [info@hansabiopharma.com](mailto:info@hansabiopharma.com)

[www.hansabiopharma.com](http://www.hansabiopharma.com)